CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...